This study evaluated the efficacy of tamsulosin in improving stent-related symptoms and quality of life in patients with in-dwelling double-J ureteral stents. A total of 42 patients (15 males and 27 females) with ureteral stent placement following ureteroscopy, percutaneous nephrolithotomy or balloon dilatation, were prospectively randomized into two groups of 21 patients. Group I received 0.4 mg tamsulosin once daily for 4 weeks and group II was a non-placebo, nontreatment control. All patients completed the International Prostate Symptom Score (IPSS) and SF-36 questionnaires at 2 and 4 weeks postoperatively. The IPSS scores for irritative and obstructive symptoms were significantly lower in group I than group II at both 2 and 4 weeks. Among the eight domains of SF-36, role limitation due to physical health and bodily pain was significantly better in group I at 2 and 4 weeks. General health was also significantly better in group I at 2 weeks. Tamsulosin improved both urinary symptoms and quality of life without causing serious side-effects.
Introduction
Ureteral stent placement is an increasingly common procedure in urological practice, due to growth in endourological surgery and extracorporeal shock wave lithotripsy. 1 Ureteral stent placement is also indicated following ureteral reconstructive surgery and as urinary diversion in patients with acute obstruction from ureteral stones. Complications following stent placement include stent-related symptoms, migration, encrustation and fragmentation of the stent. 2, 3 The degree of complications varies among patients, but commonly affect quality of life. 2 -4 α 1 -Adrenoceptors have been found in the human ureter, with the highest density in the distal ureter. 5 α 1 -Adrenoceptor antagonists dilate the lumen and reduce spasms by inhibiting basal tone and peristaltic frequency of the ureter, which may improve stent-related symptoms. 6 Tamsulosin is a N Navanimitkul, B Lojanapiwat Tamsulosin for relieving stent-related symptoms selective α 1A -and α 1D -adrenoceptor antagonist, relaxing smooth muscle in the prostate, bladder neck and distal ureter. 7 It is generally used for the treatment of benign prostatic hyperplasia, but there are several reports on its use in the treatment of distal ureteric stones. 8 -11 In the present study, the effect of tamsulosin in improving double-J stent-related symptoms and quality of life following ureteral stent placement was studied. 
Patients and methods

PATIENTS
STENT INSERTION
Blood creatinine was measured in all patients before the surgery. All patients were inserted for 4 weeks with identical double-J flexible, variable length, size 6F stents consisting of biocompatible polyurethane with a HydroPlus™ coating (Microvasive, stretch VL; Boston Scientific, Natick, MA, USA). Insertion occurred under regional or general anaesthesia and correct positioning was confirmed by plain abdominal X-ray.
No patient had any complications from the procedure.
STUDY DESIGN
Patients were prospectively randomized by random-number table into two groups. Group I received tamsulosin (Harnal ® ;
Astellas Pharma Inc., Tokyo, Japan) 0.4 mg/day for 4 weeks. Group II was the control and received neither tamsulosin nor placebo. All patients received ofloxacin 200 mg twice a day for 5 days and paracetamol (acetaminophen) on demand.
URINARY TRACT SYMPTOM ASSESSMENT
The International Prostate Symptom Score (IPSS) questionnaire 12 was used to assess patients' symptoms at 2 and 4 weeks postoperatively. The IPSS questionnaire consists of seven questions, four relating to voiding (obstructive) symptoms and three to storage (irritative) symptoms. Responses were graded on a five-point rating scale. The maximum scores for voiding and storage symptoms are 20 and 15, respectively; the higher the score, the worse are the symptoms.
QUALITY OF LIFE ASSESSMENT
Quality of life (QofL) was assessed at 2 and 4 weeks post-operatively, using the QofL section of the IPSS questionnaire and short form 36 (SF-36). 13 The SF-36 evaluates patients in eight health status domains, including physical functioning, role limitations due to physical health or emotional problems, vitality, mental health, social functioning, bodily pain and general health perceptions. Each domain comprises several questions and the responses are tallied to allocate a total score. 
STATISTICAL ANALYSES
Results
The study included 42 patients (15 men and 27 women) of which 21 (50%) had ureteral stents inserted following ureteroscopy, 13 (31%) following percutaneous nephrolithotomy and eight (19%) following ureteral balloon dilatation. Patient demographic data were comparable between the two groups ( Table 1) . None of the patients had any lower urinary tract symptoms prior to the start of the study. Table 2 shows the results of patient questionnaires regarding urinary tract symptoms and QofL at 2 and 4 weeks postoperatively. The IPSS irritative symptom and obstructive symptom scores were significantly lower in group I (tamulosin treated) than group II (control) at both time points (week 2, P ≤ 0.044; week 4, P ≤ 0.003).
Of the eight domains of the SF-36, role limitation due to physical health and bodily pain were significantly better in group I than group II at both time points (week 2, P ≤ 0.002; week 4, P ≤ 0.028). General health was significantly worse at week 2 in the control group. There were no significant differences in any of the other parameters measured.
All patients completed the 4-week study. Tamsulosin was well tolerated with two patients (9.52%) experiencing mild sideeffects, such as dizziness and headache.
Discussion
The double-J stent is a common tool used in urological surgery. 1 Despite improved design and materials, many patients still develop stent-related symptoms, sometimes necessitating early removal. 14 No statistically significant between-group differences (P > 0.05). N Navanimitkul, B Lojanapiwat Tamsulosin for relieving stent-related symptoms stent-related symptoms can be explained by multiple factors such as trigone, ureteral and renal irritation, and pressure between the bladder and renal pelvis. 14 -17 It is known that α 1D receptors are present in the ureter, 6 and that α-blockers relieve double-J stentrelated symptoms by decreasing ureteral spasm, trigone sensitivity and urine reflux during voiding. 6 Wang et al. 18 reported a prospective, randomized study comparing tamsulosin with placebo in 79 patients with double-J stents and found that tamsulosin improved stent-related symptoms and quality of life, and could be applied in routine clinical practice. Damiano et al. 19 demonstrated the positive effect of tamsulosin 0.4 mg once daily in improving stent-related urinary symptoms and pain The effect of the α-blocker, alfuzosin, was studied in patients inserted with double-J ureteral stents for unilateral ureteral stonerelated hydronephrosis. 6 When assessed with the ureteral stent symptom questionnaire (USSQ), patients who received alfuzosin 10 mg/day had better urinary symptom, pain and general health index scores than those who received placebo. These patients also had less pain and lower analgesic use. Joshi et al. 20 reported the clinical use of the USSQ for evaluation of quality of life after ureteral stent placement. Among 62 patients who completed the questionnaire, up to 80% experienced stent-related problems that affected their work performance, general health and quality of life, with the most bothersome symptoms being storage problems and incontinence.
The present study minimized within-study variations by using identical stents during endourological surgery. All patients tolerated the indwelling stents for the 4 weeks' postoperative study period. The IPSS irritative and obstructive symptom scores at 2 and 4 weeks were significantly lower and the QofL scores were significantly better in patients who received tamsulosin compared with the control group. The limitations of this study are that it was not blinded and had no placebo control; there may have been a placebo effect in patients who received the active drug.
